ClinicalTrials.gg
CompletedNCT04575597Updated Jun 28, 2023Results posted

Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)

A Phase 2/3 interventional study of Molnupiravir and Placebo in Coronavirus Disease (COVID-19), sponsored by Merck Sharp & Dohme LLC. Completed at 173 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-28.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
1,735
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing molnupiravir in COVID-19 — 4 open to participants now, 4 under way, 2 of them phase 3. molnupiravir · COVID-19.

Enrollment
5th of 14
1,735 · median 275
Started
2020
with 4 others
Phase 2/3
3 of 14
none open now
Registered
3rd of 14
by date
Lead sponsor
5 of 14
Merck Sharp & Dohme LLC

Among the 14 studies testing molnupiravir in COVID-19, this one is the 5th largest by enrollment, is one of 5 that started in 2020, is one of 3 in phase 2/3, and was the 3rd registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.

Browse COVID-19 studies →

Open to participants now

4 of the 14 studies testing molnupiravir in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About molnupiravir

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing molnupiravir in COVID-19, or all of them as a file.
02

Study summary

This study aims to evaluate the safety, tolerability and efficacy of molnupiravir (MK-4482) compared to placebo. The primary hypothesis is that molnupiravir is superior to placebo as assessed by the percentage of participants who are hospitalized and/or die through Day 29

03

Conditions studied

  • Coronavirus Disease (COVID-19)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has documentation of laboratory confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with sample collection ≤5 days prior to the day of randomization. PCR is the preferred method; however with evolving approaches to laboratory confirmation of SARS-CoV-2 infection, other molecular or antigen tests that detect viral ribonucleic acid (RNA) or protein are allowed if authorized for use in the country. Serological tests that detect host antibodies generated in response to recent or prior infection are not allowed.
  • Had initial onset of signs/symptoms attributable to COVID-19 for ≤5 days prior to the day of randomization and at least 1 of the following sign/symptom attributable to COVID-19 on the day of randomization.
  • Has mild or moderate COVID-19.
  • Has at least 1 characteristic or underlying medical condition associated with an increased risk of severe illness from COVID-19.
  • Males agree to the following during the intervention period and for at least 4 days after the last dose of study intervention: Either abstain from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent; or must agree to use .
  • Females are not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a woman of child bearing potential (); or is a WOCBP and using a contraceptive method that is highly effective (a low user dependency method OR a user dependent method in combination with barrier method), or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) for at least 4 days after the last dose of study intervention; a WOCBP must have a negative highly sensitive pregnancy test (urine or serum test is required) within 24 hours before the first dose of study intervention.

Exclusion criteria

Exclusion Criteria:

  • Is currently hospitalized or is expected to need hospitalization for COVID-19 within 48 hours of randomization.
  • Is on dialysis or has reduced estimated (eGFR) \<30 mL/min/1.73m\^2 by the Modification of Diet in Renal Disease (MDRD) equation.
  • Has any of the following conditions: (HIV) with a recent viral load >50 copies/mL (regardless of ) or an AIDS-defining illness in the past 6 months, participants with HIV may only be enrolled if on a stable antiretroviral therapy regimen; a neutrophilic granulocyte absolute count \<500/mm\^3.
  • Has a history of virus (HBV) or virus (HCV) with cirrhosis, end-stage liver disease, hepatocellular carcinoma, (AST) and/or alanine aminotransferase (ALT) >3X at screening.
  • Has a count \<100,000/μL or received a platelet transfusion in the 5 days prior to randomization.
  • Is taking or is anticipated to require any prohibited therapies.
  • Is unwilling to abstain from participating in another interventional clinical study through Day 29 with an compound or device, including those for COVID-19 therapeutics.
  • Has or other to any of the components of the study interventions as determined by the investigator.
  • Has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments including but not limited to: participants who are not expected to survive longer than 48 hours after randomization, or participants with a recent history of mechanical ventilation, or participants with conditions that could limit gastrointestinal absorption of capsule contents.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,735 participants (actual)

Study arms

  • Experimental
    Part 1: Molnupiravir 200 mg

    200 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)

    Drug: Molnupiravir

  • Experimental
    Part 1: Molnupiravir 400 mg

    400 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)

    Drug: Molnupiravir

  • Experimental
    Part 1: Molnupiravir 800 mg

    800 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)

    Drug: Molnupiravir

  • Placebo comparator
    Part 1: Placebo

    Placebo matching molnupiravir administered orally every 12 hours for 5 days (10 doses total)

    Drug: Placebo

  • Experimental
    Part 2: Molnupiravir 800 mg

    800 mg Molnupiravir (dose to be selected) administered orally every 12 hours for 5 days (10 doses total)

    Drug: Molnupiravir

  • Placebo comparator
    Part 2: Placebo

    Placebo matching molnupiravir administered orally every 12 hours for 5 days (10 doses total)

    Drug: Placebo

Interventions

  • Molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)

    Also known as: MK-4482

  • DrugPlacebo

    Placebo matching molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Were Hospitalized and/or Died Through Day 29 (Primary Pre-specified Analysis)

    The percentage of participants who were hospitalized and/or died through Day 29 is presented. Hospitalization (all cause) is defined as at least 24 hours of acute care in a hospital or similar acute care facility. Death was due to any cause. Any participants with an unknown survival status at Day 29 were treated as failure. The analysis in Part 2 was based on all participants enrolled by the pre-specified futility/early efficacy analysis and was used for demonstration of superiority to placebo for the primary efficacy outcome measure.

    Time frame: Up to 29 days

  2. Number of Participants With an Adverse Event (AE)

    The number of participants with at least 1 AE is presented. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 318 days

  3. Number of Participants Who Discontinued Study Intervention Due to an AE

    The number of participants who discontinued study intervention due to an AE is presented. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 5 days

Secondary outcomes

  1. Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Cough

    Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.

    Time frame: Up to 29 days

  2. Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Sore Throat

    Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.

    Time frame: Up to 29 days

  3. Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Nasal Congestion

    Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.

    Time frame: Up to 29 days

  4. Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Rhinorrhea

    Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.

    Time frame: Up to 29 days

  5. Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Shortness of Breath or Difficulty Breathing

    Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.

    Time frame: Up to 29 days

  6. Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Muscles or Body Aches

    Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.

    Time frame: Up to 29 days

  7. Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Fatigue

    Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.

    Time frame: Up to 29 days

  8. Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Feeling Hot or Feverish

    Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.

    Time frame: Up to 29 days

  9. Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Chills

    Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.

    Time frame: Up to 29 days

  10. Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Headache

    Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.

    Time frame: Up to 29 days

  11. Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Nausea

    Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.

    Time frame: Up to 29 days

  12. Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Vomiting

    Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.

    Time frame: Up to 29 days

  13. Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Diarrhea

    Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.

    Time frame: Up to 29 days

  14. Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Loss of Taste

    Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.

    Time frame: Up to 29 days

  15. Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Loss of Smell

    Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.

    Time frame: Up to 29 days

  16. Time to Progression of Each Targeted COVID-19 Sign/Symptom - Cough

    Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.

    Time frame: Up to 29 days

  17. Time to Progression of Each Targeted COVID-19 Sign/Symptom - Sore Throat

    Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.

    Time frame: Up to 29 days

  18. Time to Progression of Each Targeted COVID-19 Sign/Symptom - Nasal Congestion

    Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.

    Time frame: Up to 29 days

  19. Time to Progression of Each Targeted COVID-19 Sign/Symptom - Rhinorrhea

    Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.

    Time frame: Up to 29 days

  20. Time to Progression of Each Targeted COVID-19 Sign/Symptom - Shortness of Breath or Difficulty Breathing

    Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.

    Time frame: Up to 29 days

  21. Time to Progression of Each Targeted COVID-19 Sign/Symptom - Muscle or Body Aches

    Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.

    Time frame: Up to 29 days

  22. Time to Progression of Each Targeted COVID-19 Sign/Symptom - Fatigue

    Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.

    Time frame: Up to 29 days

  23. Time to Progression of Each Targeted COVID-19 Sign/Symptom - Feeling Hot or Feverish

    Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.

    Time frame: Up to 29 days

  24. Time to Progression of Each Targeted COVID-19 Sign/Symptom - Chills

    Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.

    Time frame: Up to 29 days

  25. Time to Progression of Each Targeted COVID-19 Sign/Symptom - Headache

    Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.

    Time frame: Up to 29 days

  26. Time to Progression of Each Targeted COVID-19 Sign/Symptom - Nausea

    Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.

    Time frame: Up to 29 days

  27. Time to Progression of Each Targeted COVID-19 Sign/Symptom - Vomiting

    Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.

    Time frame: Up to 29 days

  28. Time to Progression of Each Targeted COVID-19 Sign/Symptom - Diarrhea

    Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.

    Time frame: Up to 29 days

  29. Time to Progression of Each Targeted COVID-19 Sign/Symptom - Loss of Taste

    Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.

    Time frame: Up to 29 days

  30. Time to Progression of Each Targeted COVID-19 Sign/Symptom - Loss of Smell

    Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.

    Time frame: Up to 29 days

  31. Number of Participants With Responses on WHO 11-point Ordinal Outcomes Score on a Scale on Day 3

    The World Health Organization (WHO) outcome scale is an 11-point ordinal score that categorizes clinical progression. Score ranges from 0 ("uninfected") to 10 ("dead") with higher score indicating clinical progression. The number of participants at each score category is presented.

    Time frame: Day 3

  32. Number of Participants With Responses on WHO 11-point Ordinal Outcomes Score on a Scale on End of Treatment (EOT [Day 5])

    The World Health Organization (WHO) outcome scale is an 11-point ordinal score that categorizes clinical progression. Score ranges from 0 ("uninfected") to 10 ("dead") with higher score indicating clinical progression. The number of participants at each score category is presented.

    Time frame: EOT (Day 5)

  33. Number of Participants With Responses on WHO 11-point Ordinal Outcomes Score on a Scale on Day 10

    The World Health Organization (WHO) outcome scale is an 11-point ordinal score that categorizes clinical progression. Score ranges from 0 ("uninfected") to 10 ("dead") with higher score indicating clinical progression. The number of participants at each score category is presented.

    Time frame: Day 10

  34. Number of Participants With Responses on WHO 11-point Ordinal Outcomes Score on a Scale on Day 15

    The World Health Organization (WHO) outcome scale is an 11-point ordinal score that categorizes clinical progression. Score ranges from 0 ("uninfected") to 10 ("dead") with higher score indicating clinical progression. The number of participants at each score category is presented.

    Time frame: Day 15

  35. Number of Participants With Responses on WHO 11-point Ordinal Outcomes Score on a Scale on Day 29

    The World Health Organization (WHO) outcome scale is an 11-point ordinal score that categorizes clinical progression. Score ranges from 0 ("uninfected") to 10 ("dead") with higher score indicating clinical progression. The number of participants at each score category is presented.

    Time frame: Day 29

07

Results

Posted Jun 28, 2023

Participant flow

Participants were enrolled at 123 study centers in 21 countries.

Participant flow — Overall Study
MilestonePart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: Placebo
Started75777674716717
Treated74777474710701
Completed71747169675663
Not completed43554154
Withdrew: Death0001314
Withdrew: Lost to follow-up2112108
Withdrew: Withdrawal by subject22422528
Withdrew: Not recorded000002
Withdrew: Randomized by mistake without study treatment000032

Outcome measures

PrimaryPercentage of Participants Who Were Hospitalized and/or Died Through Day 29 (Primary Pre-specified Analysis)

The percentage of participants who were hospitalized and/or died through Day 29 is presented. Hospitalization (all cause) is defined as at least 24 hours of acute care in a hospital or similar acute care facility. Death was due to any cause. Any participants with an unknown survival status at Day 29 were treated as failure. The analysis in Part 2 was based on all participants enrolled by the pre-specified futility/early efficacy analysis and was used for demonstration of superiority to placebo for the primary efficacy outcome measure.

Time frame:
Up to 29 days
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Were Hospitalized and/or Died Through Day 29 (Primary Pre-specified Analysis)
Percentage of ParticipantsPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: Placebo
Percentage of Participants Who Were Hospitalized and/or Died Through Day 29 (Primary Pre-specified Analysis)1.43.94.15.47.314.1
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Difference in rates %: -4.1 · 95% CI -12.2 to 2.5
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Difference in rates %: -1.5 · 95% CI -9.9 to 6.2
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Differences in rates %: -1.3 · 95% CI -9.6 to 6.4
  • Part 2: Molnupiravir 800 mg vs Part 2: Placebo · Miettinen & Nurminen · p = 0.0012 · Difference in rates %: -6.8 · 95% CI -11.3 to -2.4
PrimaryNumber of Participants With an Adverse Event (AE)

The number of participants with at least 1 AE is presented. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
Up to 318 days
Reported as:
Count of participants · Participants
Number of Participants With an Adverse Event (AE)
ParticipantsPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: Placebo
Number of Participants With an Adverse Event (AE)29242928230239
PrimaryNumber of Participants Who Discontinued Study Intervention Due to an AE

The number of participants who discontinued study intervention due to an AE is presented. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
Up to 5 days
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Intervention Due to an AE
ParticipantsPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: Placebo
Number of Participants Who Discontinued Study Intervention Due to an AE00311020
SecondaryTime to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Cough

Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.

Time frame:
Up to 29 days
Reported as:
Median · Days
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Cough
DaysPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: Placebo
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Cough7.0 (5.0 to 10.0)6.5 (4.0 to 10.0)8.0 (6.0 to 11.0)6.0 (4.0 to 7.0)10.0 (9.0 to 11.0)10.0 (8.0 to 11.0)
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Hazard ratio (hr): 0.74 · 95% CI 0.48 to 1.13
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Hazard ratio (hr): 0.70 · 95% CI 0.46 to 1.08
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Hazard ratio (hr): 0.72 · 95% CI 0.47 to 1.11
  • Part 2: Molnupiravir 800 mg vs Part 2: Placebo · Hazard ratio (hr): 1.04 · 95% CI 0.92 to 1.18
SecondaryTime to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Sore Throat

Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.

Time frame:
Up to 29 days
Reported as:
Median · Days
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Sore Throat
DaysPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: Placebo
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Sore Throat3.0 (2.0 to 4.0)3.0 (2.0 to 5.0)4.5 (3.0 to 8.0)5.0 (3.0 to 7.0)4.0 (4.0 to 5.0)5.0 (5.0 to 6.0)
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Hazard ratio (hr): 1.49 · 95% CI 0.80 to 2.76
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Hazard ratio (hr): 1.20 · 95% CI 0.69 to 2.09
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Hazard ratio (hr): 0.93 · 95% CI 0.54 to 1.62
  • Part 2: Molnupiravir 800 mg vs Part 2: Placebo · Hazard ratio (hr): 1.12 · 95% CI 0.95 to 1.33
SecondaryTime to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Nasal Congestion

Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.

Time frame:
Up to 29 days
Reported as:
Median · Days
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Nasal Congestion
DaysPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: Placebo
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Nasal Congestion4.0 (3.0 to 6.0)4.0 (3.0 to 7.0)8.0 (5.0 to 10.0)5.0 (4.0 to 6.0)5.0 (4.0 to 6.0)6.0 (5.0 to 7.0)
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Hazard ratio (hr): 0.95 · 95% CI 0.62 to 1.46
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Hazard ratio (hr): 1.16 · 95% CI 0.75 to 1.79
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Hazard ratio (hr): 0.69 · 95% CI 0.45 to 1.07
  • Part 2: Molnupiravir 800 mg vs Part 2: Placebo · Hazard ratio (hr): 1.07 · 95% CI 0.93 to 1.23
SecondaryTime to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Rhinorrhea

Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.

Time frame:
Up to 29 days
Reported as:
Median · Days
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Rhinorrhea
DaysPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: Placebo
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Rhinorrhea4.0 (2.0 to 6.0)8.0 (5.0 to 10.0)9.0 (5.0 to 21.0)5.0 (3.0 to 6.0)5.0 (4.0 to 6.0)5.0 (5.0 to 6.0)
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Hazard ratio (hr): 1.06 · 95% CI 0.62 to 1.83
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Hazard ratio (hr): 0.71 · 95% CI 0.40 to 1.26
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Hazard ratio (hr): 0.41 · 95% CI 0.20 to 0.85
  • Part 2: Molnupiravir 800 mg vs Part 2: Placebo · Hazard ratio (hr): 1.01 · 95% CI 0.86 to 1.18
SecondaryTime to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Shortness of Breath or Difficulty Breathing

Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.

Time frame:
Up to 29 days
Reported as:
Median · Days
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Shortness of Breath or Difficulty Breathing
DaysPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: Placebo
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Shortness of Breath or Difficulty Breathing7.0 (4.0 to 22.0)4.0 (3.0 to 6.0)9.0 (4.0 to 17.0)5.0 (4.0 to 12.0)6.0 (6.0 to 8.0)9.0 (6.0 to 10.0)
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Hazard ratio (hr): 0.66 · 95% CI 0.32 to 1.34
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Hazard ratio (hr): 1.44 · 95% CI 0.76 to 2.71
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Hazard ratio (hr): 0.75 · 95% CI 0.39 to 1.42
  • Part 2: Molnupiravir 800 mg vs Part 2: Placebo · Hazard ratio (hr): 1.14 · 95% CI 0.94 to 1.37
SecondaryTime to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Muscles or Body Aches

Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.

Time frame:
Up to 29 days
Reported as:
Median · Days
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Muscles or Body Aches
DaysPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: Placebo
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Muscles or Body Aches5.0 (3.0 to 7.0)4.0 (3.0 to 4.0)4.5 (3.0 to 15.0)4.0 (3.0 to 7.0)4.0 (4.0 to 5.0)5.0 (4.0 to 5.0)
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Hazard ratio (hr): 1.03 · 95% CI 0.66 to 1.61
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Hazard ratio (hr): 1.32 · 95% CI 0.83 to 2.09
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Hazard ratio (hr): 0.76 · 95% CI 0.47 to 1.23
  • Part 2: Molnupiravir 800 mg vs Part 2: Placebo · Hazard ratio (hr): 1.01 · 95% CI 0.88 to 1.16
SecondaryTime to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Fatigue

Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.

Time frame:
Up to 29 days
Reported as:
Median · Days
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Fatigue
DaysPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: Placebo
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Fatigue7.0 (4.0 to 11.0)5.0 (3.0 to 7.0)6.0 (4.0 to 11.0)6.0 (4.0 to 10.0)6.0 (6.0 to 7.0)7.0 (6.0 to 8.0)
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Hazard ratio (hr): 0.93 · 95% CI 0.62 to 1.41
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Hazard ratio (hr): 1.09 · 95% CI 0.70 to 1.69
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Hazard ratio (hr): 1.00 · 95% CI 0.66 to 1.51
  • Part 2: Molnupiravir 800 mg vs Part 2: Placebo · Hazard ratio (hr): 1.15 · 95% CI 1.01 to 1.31
SecondaryTime to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Feeling Hot or Feverish

Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.

Time frame:
Up to 29 days
Reported as:
Median · Days
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Feeling Hot or Feverish
DaysPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: Placebo
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Feeling Hot or Feverish4.0 (3.0 to 6.0)2.0 (2.0 to 3.0)4.0 (3.0 to 5.0)3.5 (2.0 to 4.0)3.0 (3.0 to 4.0)4.0 (3.0 to 4.0)
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Hazard ratio (hr): 0.96 · 95% CI 0.54 to 1.69
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Hazard ratio (hr): 1.10 · 95% CI 0.61 to 2.00
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Hazard ratio (hr): 0.83 · 95% CI 0.50 to 1.38
  • Part 2: Molnupiravir 800 mg vs Part 2: Placebo · Hazard ratio (hr): 1.04 · 95% CI 0.90 to 1.21
SecondaryTime to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Chills

Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.

Time frame:
Up to 29 days
Reported as:
Median · Days
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Chills
DaysPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: Placebo
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Chills2.0 (2.0 to 5.0)2.0 (2.0 to 4.0)3.0 (2.0 to 3.0)4.0 (2.0 to 5.0)3.0 (2.0 to 3.0)NA (NA to NA)
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Hazard ratio (hr): 1.46 · 95% CI 0.77 to 2.76
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Hazard ratio (hr): 1.76 · 95% CI 0.92 to 3.38
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Hazard ratio (hr): 1.52 · 95% CI 0.81 to 2.86
  • Part 2: Molnupiravir 800 mg vs Part 2: Placebo · Hazard ratio (hr): 1.05 · 95% CI 0.89 to 1.24
SecondaryTime to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Headache

Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.

Time frame:
Up to 29 days
Reported as:
Median · Days
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Headache
DaysPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: Placebo
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Headache4.0 (3.0 to 6.0)4.0 (3.0 to 7.0)4.0 (3.0 to 10.0)6.0 (3.0 to 10.0)5.0 (4.0 to 5.0)5.0 (5.0 to 6.0)
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Hazard ratio (hr): 1.33 · 95% CI 0.81 to 2.20
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Hazard ratio (hr): 1.40 · 95% CI 0.85 to 2.31
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Hazard ratio (hr): 0.97 · 95% CI 0.57 to 1.65
  • Part 2: Molnupiravir 800 mg vs Part 2: Placebo · Hazard ratio (hr): 1.02 · 95% CI 0.89 to 1.18
SecondaryTime to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Nausea

Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.

Time frame:
Up to 29 days
Reported as:
Median · Days
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Nausea
DaysPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: Placebo
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Nausea5.0 (2.0 to 8.0)3.0 (2.0 to 4.0)6.0 (2.0 to 9.0)5.0 (2.0 to 9.0)4.0 (3.0 to 5.0)4.0 (3.0 to 4.0)
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Hazard ratio (hr): 0.83 · 95% CI 0.36 to 1.91
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Hazard ratio (hr): 1.37 · 95% CI 0.64 to 2.97
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Hazard ratio (hr): 0.86 · 95% CI 0.37 to 2.02
  • Part 2: Molnupiravir 800 mg vs Part 2: Placebo · Hazard ratio (hr): 0.92 · 95% CI 0.74 to 1.14
SecondaryTime to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Vomiting

Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.

Time frame:
Up to 29 days
Reported as:
Median · Days
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Vomiting
DaysPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: Placebo
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Vomiting4.0 (2.0 to 6.0)8.0 (2.0 to 14.0)5.0 (2.0 to 8.0)2.0 (2.0 to 4.0)3.0 (2.0 to 4.0)NA (NA to NA)
Statistical analysis
  • Part 2: Molnupiravir 800 mg vs Part 2: Placebo · Hazard ratio (hr): 0.68 · 95% CI 0.44 to 1.06
SecondaryTime to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Diarrhea

Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.

Time frame:
Up to 29 days
Reported as:
Median · Days
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Diarrhea
DaysPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: Placebo
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Diarrhea6.0 (2.0 to 13.0)4.0 (2.0 to 4.0)3.0 (2.0 to 6.0)2.0 (2.0 to 3.0)3.0 (3.0 to 4.0)3.0 (3.0 to 4.0)
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Hazard ratio (hr): 0.21 · 95% CI 0.06 to 0.67
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Hazard ratio (hr): 0.33 · 95% CI 0.13 to 0.83
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Hazard ratio (hr): 0.27 · 95% CI 0.09 to 0.79
  • Part 2: Molnupiravir 800 mg vs Part 2: Placebo · Hazard ratio (hr): 1.09 · 95% CI 0.87 to 1.36
SecondaryTime to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Loss of Taste

Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.

Time frame:
Up to 29 days
Reported as:
Median · Days
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Loss of Taste
DaysPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: Placebo
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Loss of Taste6.0 (4.0 to 9.0)6.0 (4.0 to 11.0)10.0 (4.0 to 19.0)9.0 (5.0 to 16.0)9.0 (8.0 to 10.0)10.0 (8.0 to 12.0)
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Hazard ratio (hr): 1.29 · 95% CI 0.74 to 2.23
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Hazard ratio (hr): 0.90 · 95% CI 0.45 to 1.80
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Hazard ratio (hr): 1.02 · 95% CI 0.55 to 1.89
  • Part 2: Molnupiravir 800 mg vs Part 2: Placebo · Hazard ratio (hr): 1.13 · 95% CI 0.94 to 1.37
SecondaryTime to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Loss of Smell

Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.

Time frame:
Up to 29 days
Reported as:
Median · Days
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Loss of Smell
DaysPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: Placebo
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Loss of Smell7.0 (6.0 to 9.0)10.0 (6.0 to 18.0)12.0 (6.0 to 19.0)12.0 (7.0 to 16.0)10.0 (9.0 to 11.0)11.0 (9.0 to 14.0)
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Hazard ratio (hr): 1.39 · 95% CI 0.83 to 2.33
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Hazard ratio (hr): 0.86 · 95% CI 0.50 to 1.48
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Hazard ratio (hr): 0.98 · 95% CI 0.56 to 1.72
  • Part 2: Molnupiravir 800 mg vs Part 2: Placebo · Hazard ratio (hr): 1.20 · 95% CI 1.01 to 1.43
SecondaryTime to Progression of Each Targeted COVID-19 Sign/Symptom - Cough

Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.

Time frame:
Up to 29 days
Reported as:
Median · Days
Time to Progression of Each Targeted COVID-19 Sign/Symptom - Cough
DaysPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: Placebo
Time to Progression of Each Targeted COVID-19 Sign/Symptom - CoughNA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Hazard ratio (hr): 0.79 · 95% CI 0.29 to 2.19
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Hazard ratio (hr): 0.91 · 95% CI 0.34 to 2.44
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Hazard ratio (hr): 1.77 · 95% CI 0.74 to 4.23
  • Part 2: Molnupiravir 800 mg vs Part 2: Placebo · Hazard ratio (hr): 0.83 · 95% CI 0.67 to 1.04
SecondaryTime to Progression of Each Targeted COVID-19 Sign/Symptom - Sore Throat

Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.

Time frame:
Up to 29 days
Reported as:
Median · Days
Time to Progression of Each Targeted COVID-19 Sign/Symptom - Sore Throat
DaysPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: Placebo
Time to Progression of Each Targeted COVID-19 Sign/Symptom - Sore ThroatNA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Hazard ratio (hr): 2.52 · 95% CI 0.98 to 6.53
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Hazard ratio (hr): 0.77 · 95% CI 0.23 to 2.52
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Hazard ratio (hr): 0.46 · 95% CI 0.11 to 1.84
  • Part 2: Molnupiravir 800 mg vs Part 2: Placebo · Hazard ratio (hr): 0.88 · 95% CI 0.66 to 1.16
SecondaryTime to Progression of Each Targeted COVID-19 Sign/Symptom - Nasal Congestion

Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.

Time frame:
Up to 29 days
Reported as:
Median · Days
Time to Progression of Each Targeted COVID-19 Sign/Symptom - Nasal Congestion
DaysPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: Placebo
Time to Progression of Each Targeted COVID-19 Sign/Symptom - Nasal CongestionNA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Hazard ratio (hr): 1.23 · 95% CI 0.46 to 3.32
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Hazard ratio (hr): 1.42 · 95% CI 0.54 to 3.74
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Hazard ratio (hr): 0.97 · 95% CI 0.34 to 2.76
  • Part 2: Molnupiravir 800 mg vs Part 2: Placebo · Hazard ratio (hr): 0.85 · 95% CI 0.66 to 1.10
SecondaryTime to Progression of Each Targeted COVID-19 Sign/Symptom - Rhinorrhea

Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.

Time frame:
Up to 29 days
Reported as:
Median · Days
Time to Progression of Each Targeted COVID-19 Sign/Symptom - Rhinorrhea
DaysPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: Placebo
Time to Progression of Each Targeted COVID-19 Sign/Symptom - RhinorrheaNA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Hazard ratio (hr): 1.02 · 95% CI 0.41 to 2.52
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Hazard ratio (hr): 0.71 · 95% CI 0.26 to 1.90
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Hazard ratio (hr): 1.24 · 95% CI 0.51 to 3.00
  • Part 2: Molnupiravir 800 mg vs Part 2: Placebo · Hazard ratio (hr): 0.90 · 95% CI 0.69 to 1.17
SecondaryTime to Progression of Each Targeted COVID-19 Sign/Symptom - Shortness of Breath or Difficulty Breathing

Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.

Time frame:
Up to 29 days
Reported as:
Median · Days
Time to Progression of Each Targeted COVID-19 Sign/Symptom - Shortness of Breath or Difficulty Breathing
DaysPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: Placebo
Time to Progression of Each Targeted COVID-19 Sign/Symptom - Shortness of Breath or Difficulty BreathingNA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Hazard ratio (hr): 0.80 · 95% CI 0.36 to 1.75
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Hazard ratio (hr): 0.73 · 95% CI 0.33 to 1.64
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Hazard ratio (hr): 0.71 · 95% CI 0.31 to 1.62
  • Part 2: Molnupiravir 800 mg vs Part 2: Placebo · Hazard ratio (hr): 0.94 · 95% CI 0.76 to 1.16
SecondaryTime to Progression of Each Targeted COVID-19 Sign/Symptom - Muscle or Body Aches

Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.

Time frame:
Up to 29 days
Reported as:
Median · Days
Time to Progression of Each Targeted COVID-19 Sign/Symptom - Muscle or Body Aches
DaysPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: Placebo
Time to Progression of Each Targeted COVID-19 Sign/Symptom - Muscle or Body AchesNA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Hazard ratio (hr): 0.59 · 95% CI 0.25 to 1.39
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Hazard ratio (hr): 0.83 · 95% CI 0.38 to 1.78
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Hazard ratio (hr): 0.59 · 95% CI 0.25 to 1.39
  • Part 2: Molnupiravir 800 mg vs Part 2: Placebo · Hazard ratio (hr): 1.16 · 95% CI 0.91 to 1.48
SecondaryTime to Progression of Each Targeted COVID-19 Sign/Symptom - Fatigue

Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.

Time frame:
Up to 29 days
Reported as:
Median · Days
Time to Progression of Each Targeted COVID-19 Sign/Symptom - Fatigue
DaysPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: Placebo
Time to Progression of Each Targeted COVID-19 Sign/Symptom - FatigueNA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Hazard ratio (hr): 0.59 · 95% CI 0.26 to 1.34
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Hazard ratio (hr): 0.62 · 95% CI 0.28 to 1.37
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Hazard ratio (hr): 0.82 · 95% CI 0.38 to 1.74
  • Part 2: Molnupiravir 800 mg vs Part 2: Placebo · Hazard ratio (hr): 0.96 · 95% CI 0.79 to 1.21
SecondaryTime to Progression of Each Targeted COVID-19 Sign/Symptom - Feeling Hot or Feverish

Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.

Time frame:
Up to 29 days
Reported as:
Median · Days
Time to Progression of Each Targeted COVID-19 Sign/Symptom - Feeling Hot or Feverish
DaysPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: Placebo
Time to Progression of Each Targeted COVID-19 Sign/Symptom - Feeling Hot or FeverishNA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Hazard ratio (hr): 1.19 · 95% CI 0.47 to 3.02
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Hazard ratio (hr): 0.80 · 95% CI 0.29 to 2.20
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Hazard ratio (hr): 0.89 · 95% CI 0.32 to 2.45
  • Part 2: Molnupiravir 800 mg vs Part 2: Placebo · Hazard ratio (hr): 0.83 · 95% CI 0.62 to 1.11
SecondaryTime to Progression of Each Targeted COVID-19 Sign/Symptom - Chills

Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.

Time frame:
Up to 29 days
Reported as:
Median · Days
Time to Progression of Each Targeted COVID-19 Sign/Symptom - Chills
DaysPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: Placebo
Time to Progression of Each Targeted COVID-19 Sign/Symptom - ChillsNA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Hazard ratio (hr): 0.82 · 95% CI 0.30 to 2.27
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Hazard ratio (hr): 0.21 · 95% CI 0.04 to 1.00
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Hazard ratio (hr): 0.66 · 95% CI 0.23 to 1.91
  • Part 2: Molnupiravir 800 mg vs Part 2: Placebo · Hazard ratio (hr): 0.87 · 95% CI 0.62 to 1.23
SecondaryTime to Progression of Each Targeted COVID-19 Sign/Symptom - Headache

Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.

Time frame:
Up to 29 days
Reported as:
Median · Days
Time to Progression of Each Targeted COVID-19 Sign/Symptom - Headache
DaysPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: Placebo
Time to Progression of Each Targeted COVID-19 Sign/Symptom - HeadacheNA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Hazard ratio (hr): 0.58 · 95% CI 0.28 to 1.20
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Hazard ratio (hr): 0.44 · 95% CI 0.20 to 0.95
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Hazard ratio (hr): 0.82 · 95% CI 0.43 to 1.59
  • Part 2: Molnupiravir 800 mg vs Part 2: Placebo · Hazard ratio (hr): 0.93 · 95% CI 0.73 to 1.19
SecondaryTime to Progression of Each Targeted COVID-19 Sign/Symptom - Nausea

Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.

Time frame:
Up to 29 days
Reported as:
Median · Days
Time to Progression of Each Targeted COVID-19 Sign/Symptom - Nausea
DaysPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: Placebo
Time to Progression of Each Targeted COVID-19 Sign/Symptom - NauseaNA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Hazard ratio (hr): 0.86 · 95% CI 0.35 to 2.11
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Hazard ratio (hr): 0.46 · 95% CI 0.16 to 1.34
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Hazard ratio (hr): 1.18 · 95% CI 0.50 to 2.79
  • Part 2: Molnupiravir 800 mg vs Part 2: Placebo · Hazard ratio (hr): 0.99 · 95% CI 0.74 to 1.32
SecondaryTime to Progression of Each Targeted COVID-19 Sign/Symptom - Vomiting

Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.

Time frame:
Up to 29 days
Reported as:
Median · Days
Time to Progression of Each Targeted COVID-19 Sign/Symptom - Vomiting
DaysPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: Placebo
Time to Progression of Each Targeted COVID-19 Sign/Symptom - VomitingNA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Hazard ratio (hr): 0.97 · 95% CI 0.06 to 15.54
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Hazard ratio (hr): 0.00
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Hazard ratio (hr): 1.00 · 95% CI 0.06 to 15.99
  • Part 2: Molnupiravir 800 mg vs Part 2: Placebo · Hazard ratio (hr): 0.76 · 95% CI 0.46 to 1.25
SecondaryTime to Progression of Each Targeted COVID-19 Sign/Symptom - Diarrhea

Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.

Time frame:
Up to 29 days
Reported as:
Median · Days
Time to Progression of Each Targeted COVID-19 Sign/Symptom - Diarrhea
DaysPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: Placebo
Time to Progression of Each Targeted COVID-19 Sign/Symptom - DiarrheaNA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Hazard ratio (hr): 1.49 · 95% CI 0.58 to 3.83
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Hazard ratio (hr): 1.14 · 95% CI 0.42 to 3.05
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Hazard ratio (hr): 1.49 · 95% CI 0.57 to 3.93
  • Part 2: Molnupiravir 800 mg vs Part 2: Placebo · Hazard ratio (hr): 0.82 · 95% CI 0.61 to 1.10
SecondaryTime to Progression of Each Targeted COVID-19 Sign/Symptom - Loss of Taste

Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.

Time frame:
Up to 29 days
Reported as:
Median · Days
Time to Progression of Each Targeted COVID-19 Sign/Symptom - Loss of Taste
DaysPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: Placebo
Time to Progression of Each Targeted COVID-19 Sign/Symptom - Loss of TasteNA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Hazard ratio (hr): 0.36 · 95% CI 0.11 to 1.21
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Hazard ratio (hr): 0.52 · 95% CI 0.20 to 1.36
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Hazard ratio (hr): 0.74 · 95% CI 0.29 to 1.89
  • Part 2: Molnupiravir 800 mg vs Part 2: Placebo · Hazard ratio (hr): 0.91 · 95% CI 0.68 to 1.20
SecondaryTime to Progression of Each Targeted COVID-19 Sign/Symptom - Loss of Smell

Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.

Time frame:
Up to 29 days
Reported as:
Median · Days
Time to Progression of Each Targeted COVID-19 Sign/Symptom - Loss of Smell
DaysPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: Placebo
Time to Progression of Each Targeted COVID-19 Sign/Symptom - Loss of SmellNA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Hazard ratio (hr): 0.35 · 95% CI 0.09 to 1.33
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Hazard ratio (hr): 0.80 · 95% CI 0.30 to 2.15
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Hazard ratio (hr): 0.51 · 95% CI 0.18 to 1.48
  • Part 2: Molnupiravir 800 mg vs Part 2: Placebo · Hazard ratio (hr): 0.81 · 95% CI 0.62 to 1.04
SecondaryNumber of Participants With Responses on WHO 11-point Ordinal Outcomes Score on a Scale on Day 3

The World Health Organization (WHO) outcome scale is an 11-point ordinal score that categorizes clinical progression. Score ranges from 0 ("uninfected") to 10 ("dead") with higher score indicating clinical progression. The number of participants at each score category is presented.

Time frame:
Day 3
Reported as:
Count of participants · Participants
Number of Participants With Responses on WHO 11-point Ordinal Outcomes Score on a Scale on Day 3
ParticipantsPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: Placebo
0200123
122111113
268726666655640
300221310
4013074
50010413
6000031
7000000
8000000
9000000
10000000
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Odds ratio (or): 3.04 · 95% CI 0.59 to 15.59
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Odds ratio (or): 1.33 · 95% CI 0.29 to 6.16
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Odds ratio (or): 0.37 · 95% CI 0.09 to 1.44
  • Part 2: Molnupiravir 800 mg vs Part 2: Placebo · Odds ratio (or): 1.19 · 95% CI 0.62 to 2.30
SecondaryNumber of Participants With Responses on WHO 11-point Ordinal Outcomes Score on a Scale on End of Treatment (EOT [Day 5])

The World Health Organization (WHO) outcome scale is an 11-point ordinal score that categorizes clinical progression. Score ranges from 0 ("uninfected") to 10 ("dead") with higher score indicating clinical progression. The number of participants at each score category is presented.

Time frame:
EOT (Day 5)
Reported as:
Count of participants · Participants
Number of Participants With Responses on WHO 11-point Ordinal Outcomes Score on a Scale on End of Treatment (EOT [Day 5])
ParticipantsPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: Placebo
030211110
195333634
258696365613593
30001149
400101013
50110721
6000052
7000001
8001001
9000010
10000000
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Odds ratio (or): 3.67 · 95% CI 1.14 to 11.88
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Odds ratio (or): 1.16 · 95% CI 0.34 to 3.98
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Odds ratio (or): 0.85 · 95% CI 0.27 to 2.68
  • Part 2: Molnupiravir 800 mg vs Part 2: Placebo · Odds ratio (or): 1.52 · 95% CI 0.96 to 2.39
SecondaryNumber of Participants With Responses on WHO 11-point Ordinal Outcomes Score on a Scale on Day 10

The World Health Organization (WHO) outcome scale is an 11-point ordinal score that categorizes clinical progression. Score ranges from 0 ("uninfected") to 10 ("dead") with higher score indicating clinical progression. The number of participants at each score category is presented.

Time frame:
Day 10
Reported as:
Count of participants · Participants
Number of Participants With Responses on WHO 11-point Ordinal Outcomes Score on a Scale on Day 10
ParticipantsPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: Placebo
0911344032
11587136881
245525649519493
30000126
400121623
511111121
60100411
7000012
8001023
9000001
10000000
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Odds ratio (or): 1.68 · 95% CI 0.82 to 3.45
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Odds ratio (or): 1.13 · 95% CI 0.55 to 2.33
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Odds ratio (or): 0.59 · 95% CI 0.27 to 1.29
  • Part 2: Molnupiravir 800 mg vs Part 2: Placebo · Odds ratio (or): 1.58 · 95% CI 1.14 to 2.20
SecondaryNumber of Participants With Responses on WHO 11-point Ordinal Outcomes Score on a Scale on Day 15

The World Health Organization (WHO) outcome scale is an 11-point ordinal score that categorizes clinical progression. Score ranges from 0 ("uninfected") to 10 ("dead") with higher score indicating clinical progression. The number of participants at each score category is presented.

Time frame:
Day 15
Reported as:
Count of participants · Participants
Number of Participants With Responses on WHO 11-point Ordinal Outcomes Score on a Scale on Day 15
ParticipantsPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: Placebo
02021131110294
115891711092
236434539433427
3000056
410121121
50010412
6010016
7000012
8001022
9000000
10000005
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Odds ratio (or): 1.41 · 95% CI 0.73 to 2.73
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Odds ratio (or): 1.00 · 95% CI 0.52 to 1.94
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Odds ratio (or): 0.67 · 95% CI 0.34 to 1.32
  • Part 2: Molnupiravir 800 mg vs Part 2: Placebo · Odds ratio (or): 1.36 · 95% CI 1.03 to 1.78
SecondaryNumber of Participants With Responses on WHO 11-point Ordinal Outcomes Score on a Scale on Day 29

The World Health Organization (WHO) outcome scale is an 11-point ordinal score that categorizes clinical progression. Score ranges from 0 ("uninfected") to 10 ("dead") with higher score indicating clinical progression. The number of participants at each score category is presented.

Time frame:
Day 29
Reported as:
Count of participants · Participants
Number of Participants With Responses on WHO 11-point Ordinal Outcomes Score on a Scale on Day 29
ParticipantsPart 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: Placebo
035403936312314
114131016126115
219191514197198
3000011
40021410
5000022
6000000
7000001
8000020
9000000
10000019
Statistical analysis
  • Part 1: Molnupiravir 200 mg vs Part 1: Placebo · Odds ratio (or): 0.76 · 95% CI 0.35 to 1.66
  • Part 1: Molnupiravir 400 mg vs Part 1: Placebo · Odds ratio (or): 0.82 · 95% CI 0.38 to 1.79
  • Part 1: Molnupiravir 800 mg vs Part 1: Placebo · Odds ratio (or): 0.82 · 95% CI 0.37 to 1.81
  • Part 2: Molnupiravir 800 mg vs Part 2: Placebo · Odds ratio (or): 1.04 · 95% CI 0.84 to 1.29
Post-hocPercentage of Participants Who Were Hospitalized and/or Died Through Day 29

The percentage of participants who were hospitalized and/or died through Day 29 is presented. Hospitalization (all cause) is defined as at least 24 hours of acute care in a hospital or similar acute care facility. Death was due to any cause. Any participants with an unknown survival status at Day 29 were treated as failure. This analysis was based on all randomized participants in Part 2 who received at least one dose of study treatment, were not hospitalized prior to the administration of the first dose of study intervention, and had reached Day 29 post treatment.

Time frame:
Up to 29 days
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Were Hospitalized and/or Died Through Day 29
Percentage of ParticipantsPart 2: Molnupiravir 800 mgPart 2: Placebo
Percentage of Participants Who Were Hospitalized and/or Died Through Day 296.89.7
Statistical analysis
  • Part 2: Molnupiravir 800 mg vs Part 2: Placebo · Difference in rates %: -3.0 · 95% CI -5.9 to -0.1

Adverse events

Collected over Up to 318 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: MK-4482 200 mg0/75 (0%)1/74 (1.4%)6/74 (8.1%)
Part 1: MK-4482 400 mg0/77 (0%)3/77 (3.9%)4/77 (5.2%)
Part 1: MK-4482 800 mg0/76 (0%)4/74 (5.4%)5/74 (6.8%)
Part 1: Placebo1/74 (1.4%)5/74 (6.8%)9/74 (12.2%)
Part 2: MK-4482 800 mg4/716 (0.6%)51/710 (7.2%)38/710 (5.4%)
Part 2: Placebo16/717 (2.2%)67/701 (9.6%)38/701 (5.4%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventPart 1: MK-4482 200 mgPart 1: MK-4482 400 mgPart 1: MK-4482 800 mgPart 1: PlaceboPart 2: MK-4482 800 mgPart 2: Placebo
COVID-19Infections and infestations0/741/772/741/7437/71053/701
COVID-19 pneumoniaInfections and infestations1/742/772/742/7429/71043/701
PneumoniaInfections and infestations0/740/771/740/742/7100/701
Diabetic metabolic decompensationMetabolism and nutrition disorders0/740/770/741/740/7101/701
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/741/770/741/741/7101/701
Peripheral vascular disorderVascular disorders0/740/770/741/740/7100/701
Thrombosis mesenteric vesselGastrointestinal disorders0/740/770/741/740/7100/701
Respiratory failureRespiratory, thoracic and mediastinal disorders0/740/770/740/746/7109/701
Pneumonia bacterialInfections and infestations0/740/770/740/743/7102/701
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/740/770/740/740/7102/701
Most frequent other events
Most frequent other events
EventPart 1: MK-4482 200 mgPart 1: MK-4482 400 mgPart 1: MK-4482 800 mgPart 1: PlaceboPart 2: MK-4482 800 mgPart 2: Placebo
COVID-19Infections and infestations3/742/773/745/7423/71017/701
DiarrhoeaGastrointestinal disorders3/742/772/744/7416/71021/701

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: PlaceboTotal
Mean49.5 ± 14.649.2 ± 14.251.0 ± 15.847.3 ± 15.244.4 ± 14.645.3 ± 15.045.6 ± 14.9
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: PlaceboTotal
Female40324130384351878
Male35453544332366857
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: PlaceboTotal
Hispanic or Latino29302333355356826
Not Hispanic or Latino46465139355358895
Unknown or Not Reported01226314
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: PlaceboTotal
American Indian or Alaska Native31256044115
Asian0100262350
Native Hawaiian or Other Pacific Islander0000000
Black or African American5863403597
White545258524004131029
More than one race13151013190202443
Unknown or Not Reported0001001
Time from Symptom Onset to Randomization (Part 1)
Time from Symptom Onset to Randomization (Part 1)(Participants)Part 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: PlaceboTotal
≤5 Days51525250——205
>5 Days24252424——97
At Increased Risk of Severe Illness from Coronavirus Disease (COVID-19) (Part 1)
At Increased Risk of Severe Illness from Coronavirus Disease (COVID-19) (Part 1)(Participants)Part 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: PlaceboTotal
Yes56585756——227
No19191918——75
Time from Symptom Onset to Randomization (Part 2)
Time from Symptom Onset to Randomization (Part 2)(Participants)Part 1: Molnupiravir 200 mgPart 1: Molnupiravir 400 mgPart 1: Molnupiravir 800 mgPart 1: PlaceboPart 2: Molnupiravir 800 mgPart 2: PlaceboTotal
≤ 3 days————342342684
> 3 days————374375749
08

Study locations

173 sites
  • Phoenix Medical Group ( Site 1822)
    Peoria, Arizona 85381, United States
  • Ruane Clinical Research Group, Inc. ( Site 2406)
    Los Angeles, California 90036, United States
  • Men's Health Foundation ( Site 1820)
    Los Angeles, California 90069, United States
  • Carbon Health Technologies Inc ( Site 2505)
    North Hollywood, California 91606, United States
  • UC Davis Medical Center ( Site 1833)
    Sacramento, California 95817, United States
  • Emerson Clinical Research Institute ( Site 1828)
    Washington, District of Columbia 20011, United States
  • JEM Research Institute ( Site 2508)
    Atlantis, Florida 33462, United States
  • Midway Immunology and Research Center ( Site 1837)
    Fort Pierce, Florida 34982, United States
  • Indago Research & Health Center, Inc ( Site 1809)
    Hialeah, Florida 33012, United States
  • Advanced Research For Health Improvement LLC ( Site 1816)
    Immokalee, Florida 34142, United States
  • Advanced Medical Research, LLC ( Site 1864)
    Miami, Florida 33174, United States
  • Advanced Research For Health Improvement LLC ( Site 1813)
    Naples, Florida 34102, United States
  • Bliss Healthcare Services ( Site 1847)
    Orlando, Florida 32806, United States
  • Javara Inc. ( Site 1869)
    Albany, Georgia 31707, United States
  • IACT Health ( Site 1818)
    Columbus, Georgia 31904, United States
  • Javara Inc. ( Site 1868)
    Fayetteville, Georgia 30214, United States
  • Loretto Hospital ( Site 1886)
    Chicago, Illinois 60644, United States
  • Jadestone Clinical Research, LLC ( Site 2502)
    Laurel, Maryland 20708, United States
  • Michigan Center of Medical Research ( Site 2500)
    Farmington Hills, Michigan 48334, United States
  • University of Nebraska Medical Center ( Site 2414)
    Omaha, Nebraska 68198, United States
  • Amici Clinical Research LLC ( Site 2507)
    Raritan, New Jersey 08869, United States
  • University of New Mexico, Health Sciences Center ( Site 1819)
    Albuquerque, New Mexico 87131, United States
  • AXCES Research Group ( Site 2418)
    Santa Fe, New Mexico 87505, United States
  • Saint Hope Foundation, Inc. ( Site 1830)
    Bellaire, Texas 77401, United States
  • The Crofoot Research Center, Inc. ( Site 1812)
    Houston, Texas 77098, United States
  • Javara Inc. ( Site 1866)
    Sugar Land, Texas 77478, United States
  • Clinical Research Partners, LLC. ( Site 2503)
    Richmond, Virginia 23226, United States
  • Swedish Medical Center First Hill ( Site 1807)
    Seattle, Washington 98104, United States
  • Fred Hutchinson Cancer Center ( Site 1829)
    Seattle, Washington 98109, United States
  • Multicare Health System ( Site 1811)
    Spokane, Washington 99204, United States
  • Multicare Health System ( Site 1814)
    University Place, Washington 98466, United States
  • Medical College Of Wisconsin ( Site 2510)
    Milwaukee, Wisconsin 53226, United States
  • Clinica Independencia ( Site 3400)
    Vicente Lopez, Buenos Aires B1605FRE, Argentina
  • Instituto Medico de la Fundacion Estudios Clinicos ( Site 3401)
    Rosario, Santa Fe 2000, Argentina
  • Chronos Pesquisa Clínica ( Site 0155)
    Brasilia, Distrito Federal 72145-424, Brazil
  • Santa Casa de Misericordia de Belo Horizonte ( Site 0150)
    Belo Horizonte, Minas Gerais 30150-221, Brazil
  • Hospital de Clinicas da Universidade Federal do Parana ( Site 0154)
    Curitiba, Parana 80060-900, Brazil
  • Hospital Tacchini ( Site 0157)
    Bento Goncalves, Rio Grande Do Sul 95700-000, Brazil
  • FUNFARME Hospital de Base Centro Integrado de Pesquisa ( Site 0151)
    Sao Jose do Rio Preto, Sao Paulo 15090-000, Brazil
  • Instituto de Infectologia Emilio Ribas ( Site 0153)
    Sao Paulo, 01246-900, Brazil
  • Centro de Pesquisa Clinica II - ICHC - FMUSP ( Site 0152)
    Sao Paulo, 05403-010, Brazil
  • Hamilton Medical Research Group ( Site 0207)
    Hamilton, Ontario L8M1K7, Canada
  • University Health Network - Toronto General Hospital ( Site 0201)
    Toronto, Ontario M5G 2N2, Canada
  • Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0200)
    Montreal, Quebec H2X 3E4, Canada
  • McGill University Health Centre ( Site 0204)
    Montreal, Quebec H4A 3J1, Canada
  • Servicios Medicos Urumed ( Site 0307)
    Rancagua, Lbtdr Gen Bernardo O Higgins 2852424, Chile
  • Clinical Research Chile SpA ( Site 0308)
    Valdivia, Los Rios 5110683, Chile
  • Clinica Universidad de los Andes ( Site 0302)
    Santiago, Region M. De Santiago 2820945, Chile
  • Fundacion Arturo Lopez Perez ( Site 0305)
    Santiago, Region M. De Santiago 7500921, Chile
  • Espacio EME ( Site 0304)
    Santiago, Region M. De Santiago 7770086, Chile
  • Centro de Investigacion Clinica UC CICUC ( Site 0309)
    Santiago, Region M. De Santiago 8330034, Chile
  • Clinica Bicentenario Spa ( Site 0306)
    Santiago, Region M. De Santiago 9160000, Chile
  • Hospital Pablo Tobon Uribe ( Site 0405)
    Medellin, Antioquia 050034, Colombia
  • Centro Cientifico Asistencial Jose Luis Accini ( Site 0416)
    Barranquilla, Atlantico 080020, Colombia
  • Clinica de la Costa Ltda. ( Site 0403)
    Barranquilla, Atlantico 080020, Colombia
  • Oncomedica S.A. ( Site 0407)
    Monteria, Cordoba 230002, Colombia
  • Caja de Compensación Familiar CAFAM. Sede Centro de Atención en Salud CAFAM Floresta ( Site 0406)
    Bogota, Cundinamarca 111211, Colombia
  • Centro de Atencion e Investigacion Medica CAIMED ( Site 0413)
    Bogota, Cundinamarca 111611, Colombia
  • Fundacion Santa Fe de Bogota ( Site 0412)
    Bogota, Distrito Capital De Bogota 110111, Colombia
  • Fundacion Cardiovascular de Colombia ( Site 0402)
    Bucaramanca, Santander 680003, Colombia
  • Fundacion Valle del Lili ( Site 0401)
    Cali, Valle Del Cauca 760032, Colombia
  • Centro Medico Imbanaco de Cali S.A ( Site 0415)
    Cali, Valle Del Cauca 760042, Colombia
  • National Center for allergies and chest ( Site 3320)
    Giza, Al Jizah 12651, Egypt
  • National Hepatology & Tropical Medicine Research Institute (NHTMRI) ( Site 3300)
    Cairo, Al Qahirah 11562, Egypt
  • Abbassia Chest Hospital ( Site 3340)
    Cairo, Al Qahirah 11591, Egypt
  • Abbassia Fever Hospital ( Site 3330)
    Cairo, Al Qahirah 11591, Egypt
  • Helwan Fever Hospital ( Site 3350)
    Cairo, Al Qahirah 12899, Egypt
  • Hopital Bichat Claude Bernard ( Site 0503)
    Paris, Ain 75018, France
  • Hopital Saint Joseph ( Site 0513)
    Marseille, Bouches-du-Rhone 13285, France
  • Groupe Hospitalier Pellegrin ( Site 0511)
    Bordeaux, Gironde 33000, France
  • CHU de la Reunion - Groupe Hospitalier Sud ( Site 0514)
    Saint Pierre Cedex, La Reunion 97448, France
  • C.H.U. de Toulouse Hopital Purpan ( Site 0501)
    Toulouse, Midi-Pyrenees 31059, France
  • Centre Hospitalier de Tourcoing ( Site 0502)
    Tourcoing, Nord 59208, France
  • CHU Hopital Saint Antoine ( Site 0505)
    Paris, 75012, France
  • Pitie Salpetriere University Hospital-Infectious Disease - Tropical Diseases ( Site 0504)
    Paris, 75013, France
  • Universitaetsklinikum Frankfurt ( Site 2302)
    Frankfurt a main, Hessen 60590, Germany
  • Universitaetsklinikum Essen ( Site 2305)
    Essen, Nordrhein-Westfalen 45147, Germany
  • ZIBP-Zentrum fur Infektiologie Berlin Prenzlauer Berg GmbH ( Site 2301)
    Berlin, 10439, Germany
  • ICH Study Center GmbH & Co.KG ( Site 2306)
    Hamburg, 20146, Germany
  • Clínica Médica Especializada en Pediatría e Infectología Pediátrica - Dr. Mario Melgar ( Site 2601)
    Guatemala, 01009, Guatemala
  • Clinica Privada Dr. Jose Francisco Flores Lopez ( Site 2600)
    Guatemala, 01015, Guatemala
  • Hadassah Medical Center. Ein Kerem ( Site 2100)
    Jerusalem, 9112001, Israel
  • Asl Napoli 1 Centro ( Site 0610)
    Napoles, Napoli 80145, Italy
  • Policlinico S. Orsola-Malpighi ( Site 0604)
    Bologna, 40138, Italy
  • IRCCS Ospedale Policlinico San Martino ( Site 0603)
    Genova, 16132, Italy
  • Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico ( Site 0606)
    Milano, 20122, Italy
  • Ospedale San Raffaele ( Site 0605)
    Milano, 20127, Italy
  • ASST Fatebenefratelli-Ospedale Sacco ( Site 0601)
    Milano, 20157, Italy
  • Ospedale Niguarda ( Site 0608)
    Milano, 20162, Italy
  • AOU Policlinico Paolo Giaccone ( Site 0609)
    Palermo, 90127, Italy
  • Istituto Nazionale per Le Malattie Infettive Lazzaro Spallanzani ( Site 0600)
    Roma, 00149, Italy
  • Ospedale Amedeo di Savoia, Malattie Infettive ( Site 0602)
    Torino, 10149, Italy
  • Azienda Sanitaria Universitaria Friuli Centrale -ASU FC ( Site 0607)
    Udine, 33100, Italy
  • Chiba Aoba Municipal Hospital ( Site 0702)
    Chiba, 260-0852, Japan
  • Den-en-chofu family clinic ( Site 0701)
    Tokyo, 145-0071, Japan
  • Center Hospital of the National Center for Global Health and Medicine ( Site 0700)
    Tokyo, 162-8655, Japan
  • Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran ( Site 0802)
    Ciudad de mexico, Distrito Federal 14080, Mexico
  • CAIMED México ( Site 0814)
    Mexico City, Distrito Federal 06760, Mexico
  • Hospital Regional de Alta Especialidad del Bajio ( Site 0807)
    Leon, Guanajuato 37660, Mexico
  • Hospital Civil de Guadalajara Fray Antonio Alcalde ( Site 0800)
    Guadalajara, Jalisco 44280, Mexico

Showing the first 100 of 173 sites across 23 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Caraco Y, Crofoot GE, Moncada PA, Galustyan AN, Musungaie DB, Payne B, Kovalchuk E, Gonzalez A, Brown ML, Williams-Diaz A, Gao W, Strizki JM, Grobler J, Du J, Assaid CA, Paschke A, Butterton JR, Johnson MG, De Anda C. Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults. NEJM Evid. 2022 Feb;1(2):EVIDoa2100043. doi: 10.1056/EVIDoa2100043. Epub 2021 Dec 16. PubMed 38319179 ↗
  • Johnson MG, Puenpatom A, Moncada PA, Burgess L, Duke ER, Ohmagari N, Wolf T, Bassetti M, Bhagani S, Ghosn J, Zhang Y, Wan H, Williams-Diaz A, Brown ML, Paschke A, De Anda C. Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19 : A Randomized, Placebo-Controlled Trial. Ann Intern Med. 2022 Aug;175(8):1126-1134. doi: 10.7326/M22-0729. Epub 2022 Jun 7. PubMed 35667065 ↗
  • Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, Martin-Quiros A, Caraco Y, Williams-Diaz A, Brown ML, Du J, Pedley A, Assaid C, Strizki J, Grobler JA, Shamsuddin HH, Tipping R, Wan H, Paschke A, Butterton JR, Johnson MG, De Anda C; MOVe-OUT Study Group. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med. 2022 Feb 10;386(6):509-520. doi: 10.1056/NEJMoa2116044. Epub 2021 Dec 16. PubMed 34914868 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in May 2022, 18 months.

Results were first posted in Jun 2023, 1 year 1 month after primary completion.

Of 73 industry-sponsored phase 2/3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 18 months is above that.

Counting every sponsor, half of 168 studies reached it within 11 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2020
First posted
Oct 5, 2020
StartActual
Oct 19, 2020
Primary completionActual
May 5, 2022
CompletionActual
May 5, 2022
Results first posted
Jun 28, 2023
Last update
Jun 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04575597
Responsible party
Sponsor
First posted
Oct 5, 2020
Start date
Oct 19, 2020
Primary completion
May 5, 2022
Completion
May 5, 2022
Results posted
Jun 28, 2023
Last update
Jun 28, 2023

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Molnupiravir

Start the discussion